A systematic review of the literature on mechanisms of 5-nitroimidazole resistance in
5-Nitroimidazole
Trichomonas vaginalis
drug resistance
metronidazole
tinidazole
Journal
Parasitology
ISSN: 1469-8161
Titre abrégé: Parasitology
Pays: England
ID NLM: 0401121
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
pubmed:
31
7
2020
medline:
16
6
2021
entrez:
31
7
2020
Statut:
ppublish
Résumé
Trichomonas vaginalis is the most common non-viral sexually transmitted infection. 5-Nitroimidazoles [metronidazole (MTZ) and tinidazole (TDZ)] are FDA-approved treatments. To better understand treatment failure, we conducted a systematic review on mechanisms of 5-nitroimidazole resistance. PubMed, ScienceDirect and EMBASE databases were searched using keywords Trichomonas vaginalis, trichomoniasis, 5-nitroimidazole, metronidazole, tinidazole and drug resistance. Non-English language articles and articles on other treatments were excluded. The search yielded 606 articles, of which 550 were excluded, leaving 58 articles. Trichomonas vaginalis resistance varies and is higher with MTZ (2.2-9.6%) than TDZ (0-2%). Resistance can be aerobic or anaerobic and is relative rather than absolute. Differential expression of enzymes involved in trichomonad energy production and antioxidant defenses affects 5-nitroimidazole drug activation; reduced expression of pyruvate:ferredoxin oxidoreductase, ferredoxin, nitroreductase, hydrogenase, thioredoxin reductase and flavin reductase are implicated in drug resistance. Trichomonas vaginalis infection with Mycoplasma hominis or T. vaginalis virus has also been associated with resistance. Trichomonas vaginalis has two genotypes, with greater resistance seen in type 2 (vs type 1) populations. 5-Nitroimidazole resistance results from differential expression of enzymes involved in energy production or antioxidant defenses, along with genetic mutations in the T. vaginalis genome. Alternative treatments outside of the 5-nitroimidazole class are needed.
Sections du résumé
BACKGROUND
Trichomonas vaginalis is the most common non-viral sexually transmitted infection. 5-Nitroimidazoles [metronidazole (MTZ) and tinidazole (TDZ)] are FDA-approved treatments. To better understand treatment failure, we conducted a systematic review on mechanisms of 5-nitroimidazole resistance.
METHODS
PubMed, ScienceDirect and EMBASE databases were searched using keywords Trichomonas vaginalis, trichomoniasis, 5-nitroimidazole, metronidazole, tinidazole and drug resistance. Non-English language articles and articles on other treatments were excluded.
RESULTS
The search yielded 606 articles, of which 550 were excluded, leaving 58 articles. Trichomonas vaginalis resistance varies and is higher with MTZ (2.2-9.6%) than TDZ (0-2%). Resistance can be aerobic or anaerobic and is relative rather than absolute. Differential expression of enzymes involved in trichomonad energy production and antioxidant defenses affects 5-nitroimidazole drug activation; reduced expression of pyruvate:ferredoxin oxidoreductase, ferredoxin, nitroreductase, hydrogenase, thioredoxin reductase and flavin reductase are implicated in drug resistance. Trichomonas vaginalis infection with Mycoplasma hominis or T. vaginalis virus has also been associated with resistance. Trichomonas vaginalis has two genotypes, with greater resistance seen in type 2 (vs type 1) populations.
DISCUSSION
5-Nitroimidazole resistance results from differential expression of enzymes involved in energy production or antioxidant defenses, along with genetic mutations in the T. vaginalis genome. Alternative treatments outside of the 5-nitroimidazole class are needed.
Identifiants
pubmed: 32729451
doi: 10.1017/S0031182020001237
pii: S0031182020001237
pmc: PMC7677174
mid: NIHMS1626160
doi:
Substances chimiques
Antiprotozoal Agents
0
Tinidazole
033KF7V46H
Metronidazole
140QMO216E
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1383-1391Subventions
Organisme : NIAID NIH HHS
ID : U19 AI113212
Pays : United States
Références
Parasitology. 1993 Jan;106 ( Pt 1):31-7
pubmed: 8479798
Biochem Pharmacol. 1986 May 15;35(10):1703-8
pubmed: 3486660
Int J Clin Pharmacol Ther Toxicol. 1984 Feb;22(2):63-72
pubmed: 6698665
Mol Biochem Parasitol. 1985 Jan;14(1):29-40
pubmed: 3872412
Iran J Parasitol. 2013 Jul;8(3):402-7
pubmed: 24454433
Antimicrob Agents Chemother. 2014 May;58(5):2938-43
pubmed: 24550324
Clin Infect Dis. 2007 Jan 1;44(1):13-22
pubmed: 17143809
J Infect Dis. 1986 May;153(5):948-55
pubmed: 3486237
J Antimicrob Chemother. 1979 May;5(3):315-6
pubmed: 113378
J Reprod Med. 2001 Jun;46(6):545-9
pubmed: 11441678
Clin Infect Dis. 2007 Nov 15;45(10):1319-26
pubmed: 17968828
Curr Opin Infect Dis. 2020 Feb;33(1):73-77
pubmed: 31789671
Indian J Med Microbiol. 2011 Apr-Jun;29(2):152-7
pubmed: 21654110
Mol Biochem Parasitol. 1986 May;19(2):111-6
pubmed: 3487729
Mol Biochem Parasitol. 2010 May;171(1):17-24
pubmed: 20093143
J Gen Microbiol. 1985 Jan;131(1):87-92
pubmed: 2985740
Br J Vener Dis. 1960 Sep;36:154-62
pubmed: 13725181
Clin Infect Dis. 2011 Jan 15;52(2):163-70
pubmed: 21288838
J Eukaryot Microbiol. 1993 May-Jun;40(3):262-9
pubmed: 8508165
J Biol Chem. 1985 Mar 25;260(6):3697-702
pubmed: 2982874
Folia Microbiol (Praha). 1987;32(4):345-8
pubmed: 3499366
J Eukaryot Microbiol. 2019 Mar;66(2):309-315
pubmed: 30047563
Sex Transm Dis. 2001 Feb;28(2):115-6
pubmed: 11234785
Sex Transm Infect. 2004 Apr;80(2):91-5
pubmed: 15054166
Biochem Pharmacol. 1986 Jan 1;35(1):59-61
pubmed: 3940527
Am J Trop Med Hyg. 2010 Dec;83(6):1283-6
pubmed: 21118935
Emerg Infect Dis. 2012 Jun;18(6):939-43
pubmed: 22608054
JAMA. 1989 Jan 27;261(4):571-6
pubmed: 2783346
F1000Res. 2019 Sep 20;8:
pubmed: 31583080
Int J STD AIDS. 2019 Apr;30(5):496-504
pubmed: 30626281
Iran J Parasitol. 2010 Dec;5(4):9-14
pubmed: 22347260
Exp Parasitol. 2012 Jul;131(3):393-8
pubmed: 22584035
Aliment Pharmacol Ther. 1998 Jun;12(6):551-5
pubmed: 9678815
Parasitol Res. 2018 Mar;117(3):841-847
pubmed: 29368037
Mol Biochem Parasitol. 1999 Jan 25;98(2):203-14
pubmed: 10080389
Sex Transm Dis. 2010 Jul;37(7):440-4
pubmed: 20351623
PLoS Negl Trop Dis. 2012;6(3):e1573
pubmed: 22479659
MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137
pubmed: 26042815
Int J Parasitol. 1999 Feb;29(2):199-212
pubmed: 10221623
Microbios. 1992;71(286):55-64
pubmed: 1406344
Exp Parasitol. 2001 Feb;97(2):102-10
pubmed: 11281707
Indian J Med Microbiol. 2008 Apr-Jun;26(2):158-9
pubmed: 18445954
Mol Microbiol. 2009 Apr;72(2):518-36
pubmed: 19415801
J Clin Microbiol. 2000 Aug;38(8):3004-9
pubmed: 10921968
Antimicrob Agents Chemother. 2005 Dec;49(12):5033-6
pubmed: 16304169
J Parasitol. 2006 Feb;92(1):196-9
pubmed: 16629339
J Eukaryot Microbiol. 2010 Mar-Apr;57(2):171-6
pubmed: 20015182
J Gen Microbiol. 1985 Apr;131(4):849-53
pubmed: 3921658
Mol Biochem Parasitol. 1994 Jul;66(1):127-37
pubmed: 7984175
Sex Transm Infect. 2013 Sep;89(6):426-33
pubmed: 23605851
Res Microbiol. 2017 Nov - Dec;168(9-10):882-891
pubmed: 28366838
Biochem Pharmacol. 1986 Jan 1;35(1):61-4
pubmed: 3000386
Antimicrob Agents Chemother. 1983 Nov;24(5):667-73
pubmed: 6607028
Mol Biochem Parasitol. 2002 Apr 30;121(1):153-7
pubmed: 11985873
Gene. 2004 Mar 31;329:81-92
pubmed: 15033531
Can Med Assoc J. 1962 Apr 7;86(14):665
pubmed: 20327097
Parasitol Res. 2010 Sep;107(4):1023-7
pubmed: 20652315
Ann Trop Med Parasitol. 2003 Jul;97(5):499-504
pubmed: 12930613
Exp Parasitol. 2017 Nov;182:34-36
pubmed: 28935536
BMC Evol Biol. 2001;1:11
pubmed: 11734059
Parasitology. 2001 Jul;123(Pt 1):45-56
pubmed: 11467782
Mol Biochem Parasitol. 2012 Jun;183(2):177-83
pubmed: 22449940
Infect Genet Evol. 2015 Aug;34:181-7
pubmed: 26160539
Microbiology (Reading). 1994 Sep;140 ( Pt 9):2489-94
pubmed: 7952198
Clin Microbiol Rev. 2017 Jul;30(3):811-825
pubmed: 28539504
Proc Natl Acad Sci U S A. 1992 May 15;89(10):4402-6
pubmed: 1374901
Antimicrob Agents Chemother. 2006 Dec;50(12):4209-10
pubmed: 17000740
J Pharmacol Pharmacother. 2014 Jan;5(1):74-5
pubmed: 24554918
FEMS Immunol Med Microbiol. 2001 Dec;32(1):27-32
pubmed: 11750218
Parasitol Res. 2006 Dec;100(1):123-30
pubmed: 16847608
PLoS One. 2015 Dec 08;10(12):e0143304
pubmed: 26646541
Am J Trop Med Hyg. 2000 Apr;62(4):441-5
pubmed: 11220758
Mol Biochem Parasitol. 1992 Nov;56(1):79-88
pubmed: 1475004
Mol Microbiol. 2014 Jan;91(1):198-208
pubmed: 24256032
Clin Infect Dis. 2018 Jul 2;67(2):211-217
pubmed: 29554238
Am J Obstet Gynecol. 2017 Dec;217(6):678.e1-678.e9
pubmed: 28867602
Genome Biol Evol. 2017 Jun 1;9(6):1658-1672
pubmed: 28633446
Iran J Parasitol. 2012;7(3):24-30
pubmed: 23109958
Biochem Pharmacol. 1986 Jan 1;35(1):37-41
pubmed: 3940525
Microbiology (Reading). 2002 Aug;148(Pt 8):2467-2477
pubmed: 12177340
Sex Transm Dis. 2011 Oct;38(10):962-3
pubmed: 21934573
Sex Transm Dis. 2014 Jun;41(6):369-76
pubmed: 24825333
Parasitol Res. 2017 Nov;116(11):3125-3130
pubmed: 28956167
J Parasitol. 1964 Jun;50:345-64
pubmed: 14169529
Ann Inst Pasteur (Paris). 1959 Feb;96(2):238-41
pubmed: 13627590
Clin Infect Dis. 2001 Oct 15;33(8):1341-6
pubmed: 11565074
Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S837-48
pubmed: 26602621
J Antimicrob Chemother. 1982 Aug;10(2):84-7
pubmed: 6749789
J Eukaryot Microbiol. 1997 Nov-Dec;44(6):545-52
pubmed: 9435127
Antimicrob Agents Chemother. 2009 Feb;53(2):458-64
pubmed: 19015349
FEMS Microbiol Lett. 2003 Sep 26;226(2):379-84
pubmed: 14553936
Genome Biol Evol. 2012;4(10):1017-29
pubmed: 22975721